Gene Expression of Survivin and Its Spliced Isoforms Associated With Proliferation and Aggressive Phenotypes of Prostate Cancer

Urology

Volumn 72, Issue 6, 2008, Pages 1229-1233

  Koike, Hidekazu ^a   Sekine, Yoshitaka ^a   Kamiya, Makoto ^a   Nakazato, Haruki ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; SMALL INTERFERING RNA; SURVIVIN; SURVIVIN 2ALPHA; SURVIVIN 2B; SURVIVIN DELTAEX3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RNA SPLICING; RNA, SMALL INTERFERING;

EID: 56449095217     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.12.064     Document Type: Article

References (30)

1. Altieri D.C., and Marchisio P.C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79 (1999) 1327-1333
2. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 (2005) 360-372
3. Takai N., Miyazaki T., Nishida M., et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 184 (2002) 105-116
4. Dong Y., Sui L., Watanabe Y., et al. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 22 (2002) 2377-2383
5. Islam A., Kageyama H., Takada N., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
6. Kato J., Kuwabara Y., Mitani M., et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95 (2001) 92-95
7. Mahotka C., Wenzel M., Springer E., et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097-6102
8. Caldas H., Jiang Y., Holloway M.P., et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24 (2005) 1994-2007
9. Caldas H., Honsey L.E., and Altura R.A. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer 4 (2005) 1-9
10. Mahotka C., Krieq T., Krieq A., et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100 (2002) 30-36
11. Krajewska M., Krajewski S., Banares S., et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9 (2003) 4914-4925
12. Kaur P., Kallakury B.S., Sheehan C.E., et al. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128 (2004) 39-43
13. Olie R.A., Simoes-Wust A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
14. Pennati M., Binda M., Colella G., et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23 (2004) 386-394
15. Hayashi N., Asano K., Suzuki H., et al. Adenoviral infection of survivin antisense sensitizes prostate cancer to etoposide in vivo. Prostate 65 (2005) 10-19
16. Zhang M., Mukherjee N., Bermudez R.S., et al. Adenovirus-mediated inhibition of survivin expression sensitize human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 (2005) 293-302
17. Pennati M., Binda M., Colella G., et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120 (2003) 648-654
18. Suzuki K., Koike H., Matsui H., et al. Genistein, a soy isofravone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 99 (2002) 846-852
19. Kishi H., Igawa M., Kikuno N., et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171 (2004) 1855-1860
20. Noton E.A., Colnaghi R., Tate S., et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281 (2006) 1286-1295
21. Span P.N., Tjan-Heijnen V.C., Heuvel J.J., et al. Do the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer?. Clin Chem 52 (2006) 1693-1700
22. Futakuchi H., Ueda M., Kanda K., et al. Transcriptional expression of surviving and its splice variants in cervical carcinomas. Int J Gynecol Cancer 17 (2007) 1092-1098
23. Taubert H., Kappler M., Bache M., et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 24 (2005) 5258-5261
24. Chen J., Wu W., Tahir S.K., et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2 (2000) 235-241
25. Yamamoto T., Manome Y., Nakamura M., et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 38 (2002) 2316-2324
26. Choi K.S., Lee T.H., and Jung M.H. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10 (2003) 87-95
27. Mesri M., Wall N.R., Li J., et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108 (2001) 981-990
28. Elbashir S., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15 (2001) 188-200
29. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12 (2005) 217-227
30. Shariat S.F., Ashfaq R., Roehrborn C.G., et al. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 174 (2005) 2046-2050